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PERSPECTIVES IN CLINICAL NEPHROLOGY
The renal risks of smoking
The adverse health effects of smoking are widely known. The
health problems and costs associated with smoking have recently
been extensively reviewed [1—3]. Smoking-induced morbidity in-
cludes: (i) cardiovascular complications [4, 5], (ii) cancer [6—8] (of
interest to the nephrologist this includes kidney [9—18], ureter and
bladder cancer [19—23]), (iii) pulmonary disease [24], and (iv)
numerous other problems, such as preeclampsia and eclampsia,
gastric ulcer. A direct and significant dose-risk relationship for
developing renal cell carcinoma has been reported to vary be-
tween 1.1 for moderate and 3.8 for heavy smokers [9, 10].
Concerning the risk of developing uroepithelial cell cancer,
cigarette smoking is the single most important risk factor apart
from industrial exposure to carcinogens [23]. According to differ-
ent authors the relative risk for smokers in general varies between
1.5 and 3.0 [25]. Several case-control studies have revealed a clear
dose-response relationship; for the heaviest smokers the relative
risks has ranged from 4.7 to 7.9 in different studies [26].
Smoking is the cause of premature mortality accounting for
more than 500,000 and 400,000 deaths/year in the European
Union and the USA, respectively [1, 27]. The basic problem is the
addictive property of nicotine in tobacco smoke [28], which
explains the almost complete lack of change in the prevalence of
smoking in recent years in Germany and the USA, despite
increasing knowledge and awareness of its adverse effects [3, 27,
29]. In fact, the prevalence of smoking in adolescents is actually
increasing.
We wish to argue that the kidney is also an important target
organ of smoking-induced damage. Apparently because there is
less information available on this point, this issue has been
neglected by nephrologists. We shall marshal considerable evi-
dence to support the notion of important adverse effects of
smoking on renal function in diabetic nephropathy and shall
provide some preliminary evidence that the injurious effect of
smoking on the kidney applies to primary chronic renal diseases as
well.
Epidemiological information
Smoking and the risk of albuminuria in patients with primary
(essential) hypertension
A relation between proteinuria and primary hypertension has
been noted since the early years of this century [30]. Proteinuria
and, as examined more recently, albuminuria is found in 10% to
18% of patients with essential hypertension [31, 32]. The preva-
lence was less (4 to 6%) in studies which included borderline
hypertension [33, 34]. In several studies smoking emerged as an
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independent predictor of (micro)albuminuria in otherwise healthy
patients with primary hypertension. For instance, Mimran et al
[35] studied lean subjects with essential hypertension and found
that the prevalence of microalbuminuria was almost double in
smokers as compared to non-smokers. Homer et al [36] recently
examined albumin excretion in the morning urine of 631 hyper-
tensive and non-hypertensive patients. By multivariate analysis
smoking emerged as the determinant which exhibited the most
significant association with albuminuria. Since urinary albumin is
a sensitive marker of glomerular injury [37], it is conceivable that
the relationship of smoking to albuminuria indicates direct or
indirect renal damage induced by smoking. In a study examining
urines of 62,300 participants in the Kaiser-Permanente program,
Dales et al [38] noted that proteinuria is more common in
smokers and is more pronounced in heavy as compared to light
smokers. In addition, hematuria tended to be more prevalent in
smokers, but alcohol use was a confounder in these relationships.
In this context, it is of interest that in the Multiple Risk Factor
Intervention Trial (MRFIT) an increased risk for end-stage renal
disease (ESRD) was found for smokers as compared to non-
smokers [39]. Such increased relative risk of ESRD related to
smoking (up to 1.69 for heavy smokers) was independent of age,
ethnicity, income, blood pressure, diabetes mellitus, prior history
of myocardial infarction, or serum cholesterol.
Smoking and diabetic nephropathy
In diabetic patients smoking increases mortality two- to three-
fold, mainly as a result of cardiovascular complications [40—47].
The risk is particularly high in diabetic patients with ESRD who
smoke [48, 49] and may be aggravated by the cumulation of
nicotine in patients with renal failure [50]. Apart from such effects
on cardiovascular complications, considerable evidence has accu-
mulated pointing to adverse renal effects of smoking on the
evolution of diabetic nephropathy. An initial communication by
Christiansen in 1978 suggesting smoking as an independent risk
factor for diabetic nephropathy [51] attracted little attention. In
the early 80s a number of studies appeared examining the
influence of blood pressure and glycemic control on the evolution
of diabetic nephropathy and retinopathy, but as pointed out by
MUhihauser, Sawicki and Berger [52] smoking was not even
considered as a potential confounder.
Considerable evidence, however, has accumulated that in insu-
lin dependent diabetes mellitus (IDDM) the risk to develop
microalbuminuria or proteinuria is substantially higher in smokers
[52—57]. For example, Chase et al [56] reported that in a group of
359 young subjects with IDDM the prevalence of borderline (>
7.6 tg/min) and abnormal (> 30 j.Lg/min) albumin excretion rates
was 2.8-fold higher in smokers than non-smokers. Smoking has
adverse effects on four different aspects of albumin excretion: (i)
it increases the risk of microalbuminuria [56]; (ii) it shortens the
time interval between onset of diabetes and onset of albuminuria
or proteinuria [48, 49]; (iii) it accelerates the rate of progression
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from microalbuminuria to persistent proteinuria, that is, overt
diabetic nephropathy [52, 51; and (iv) it accelerates the rate of
progression of diabetic nephropathy to ESRD [49, 58]. Sawicki et
al [59] calculated the adjusted odds ratio for progression of
diabetic nephropathy, defined as an increase in proteinuria >
20% per year and/or a reduction of glomerular filtration rate
(GFR) > 20%. The odds ratio was higher by a factor of 2.74 for
each 10 cigarette pack years. In this study all patients were on
intensified insulin and antihypertensive therapy, so that confound-
ing effects of hyperglycemia and hypertension were minimized. In
the study of Biesenbach, Janko and Zazzgornik [58] the rate of
loss of GFR was higher by a factor of 1.44 in smoking as compared
to non-smoking patients with IDDM.
The situation is somewhat more complex in non-insulin depen-
dent diabetes mellitus (NIDDM). It has become apparent that
smokers have a greater risk to develop NIDDM [60, 61]. In a
prospective study on 41,810 non-diabetic males aged 40 to 75
years Rimm et a! [60] found that the relative risk to develop
NIDDM during six years of observation was 1.94-fold higher in
heavy smokers (25 or more cigarettes/day) as compared to
non-smokers. In another prospective study on 7,735 males (40 to
59 years) current smoking was associated with a 50% increase of
the risk to develop NIDDM [61]. This increased risk may be
related to the fact that smoking aggravates insulin resistance in
healthy smokers, at least in some studies (vide infra).
When patients with newly diagnosed NIDDM were examined in
cross-sectional studies an association was found between smoking
and urinary albumin/creatinine ratio [62] as well as the frequency
of microalbuminuria [63]. Analogous to the situation in IDDM
prospective studies also have documented that smoking is an
independent predictor for the de novo development of microalbu-
minuria in patients with NIDDM [64]. In a large, population-
based cross-sectional study on patients with established NIDDM,
cigarette smoking emerged as an independent variable related to
micro- and macroalbuminuria [65]. This finding was confirmed by
other authors [661. Furthermore, similar to the situation in
IDDM, in patients with NIDDM smoking is also related to
progression from the stages of microalbuminuria to gross protein-
uria (> 300 mg/day). In a prospective study including 794 patients
with NIDDM who had no proteinuria at baseline the relative risk
of developing gross proteinuria (> 300 mg/day) during four years
of observation was 2- to 2.5-fold higher in heavy smokers as
compared to subjects who had never smoked [671. Finally, Biesen-
bach, Janko and Zazgornik [58] reported that in patients with
NIDDM the rate of loss of GFR, that is, measured as endogenous
creatinine clearance, was increased in smokers by a risk factor of
1.66.
It should be pointed out that not only extrarenal macrovascular,
but also nonrenal microvascular complications of diabetes tend to
be more frequent in smokers. There is at least some information
[52, 56, 68], though not consistently confirmed [54, 69, 70], that
the evolution of diabetic retinopathy is more malignant in smok-
ers. In addition, necrobiosis lipoidica diabeticorum is more com-
mon in smokers [71], possibly as a result of impaired skin
microcirculation in smokers [72].
Renal artery stenosis and ischemic nephropathy are common in
diabetes, particularly in NIDDM [731. Although epidemiological
information on this point is not available, one would anticipate
that the risk is aggravated in diabetic patients who smoke. This
view is based on the observation that in general smoking is a
predictor of significant renal artery stenosis as well as atheroem-
bolic renal disease [74, 75]; thus, a similar relationship in diabetic
patients would be expected.
In summary, there is substantial evidence for the adverse effect
of smoking on renal functional deterioration in IDDM and
NIDDM. The number of studies in IDDM patients is, however,
larger than those dealing with NIDDM patients. The evidence for
adverse effects of smoking are therefore more robust in the
former than in the latter group.
In this context it is noteworthy that there is evidence that
cessation of smoking is beneficial for renal function in diabetic
patients. In patients with IDDM albuminuria improved signifi-
cantly when patients stopped smoking [56]. According to Sawicki
et a! [59] progression of diabetic nephropathy was found in 53%
of current smokers, but only 33% of patients who had stopped
smoking and 11% of non-smokers.
Other renal diseases
Very little information is available concerning adverse effects of
smoking on the evolution of other chronic renal diseases. Never-
theless, the fragmentary information that is available raises the
suspicion that the deleterious effect of smoking on renal function
is not restricted to essential hypertension and diabetic nephrop-
athy.
In autosomal dominant polycystic kidney disease (ADPKD)
Chapman et a! [76] found that patients with established protein-
uria had not only higher mean arterial pressures and more severe
renal cystic involvement, but also had a greater pack year smoking
history than did their nonproteinuric counterparts. In lupus
nephritis, a retrospective cohort study of 160 adults (median
follow-up 6.4 years) documented that smoking at the time of onset
of nephritis was an independent risk factor for the more rapid
development of ESRD [77]. The median time interval to terminal
renal failure was 145 months in smokers and more than 273
months in non-smokers. This observation is particularly impor-
tant, because the effect of smoking was independent of hyperten-
sion and immunosuppressive treatment.
Concerning a possible causal link between tobacco and the
development of primary glomerulonephritis, Yaqoob et al [78]
reported that there was no significant correlation in a case-control
study including 55 patients and 55 normal subjects. Of interest,
however, in anti-glomerular basement membrane (anti-GBM)
disease current smoking is significantly associated with pulmonary
hemorrhage (Goodpasture syndrome) [79]. The hypothesis has
been advanced that the Goodpasture antigen is less accessible in
the pulmonary microcirculation as compared to the glomerulus.
Accessibility was thought to be increased, however, under the
influence of organic solvents, irritants, or tobacco smoking, that is,
agents causing latent pulmonary injury and loss of sequestration
of the Goodpasture antigen. On the other hand, there is no
positive evidence that smoking aggravates the course of anti-GBM
glomeru!onephritis [80].
The risk of atherosclerotic disease, particularly arterioocclusive
disease of the lower limb, is strikingly higher in smokers. In
parallel, Appe! et a! [74] reported that smoking was a predictor of
significant renal artery stenosis as well. The mechanisms by which
smoking increases the risk of atherosclerosis have been discussed
elsewhere [81—84]. An interesting hypothesis to explain the
different susceptibility of individuals to smoking-induced athero-
genesis has been proposed by Wang et al [85]: the risk appears to
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be excessively high in patients who are homozygous for the
endothelial nitric oxide synthase 4a (ecNOS4a) gene. This geno-
type predisposes to endothelial dysfunction and is associated with
an increased coronary risk in smokers [85].
Known direct effects of smoking (and nicotine) on the kidney
Smoking and/or nicotine have three major known effects on the
kidney: (i) on renal hemodynamics, (ii) on water diuresis and
electrolyte excretion, and (iii) on the proximal tubule.
In an experimental study nicotine was infused into the renal
artery [86]; this caused an increase in GFR, sodium and chloride
excretion and urine flow. In this study arterial pressure or renal
blood flow remained unchanged. In contrast, after administration
of propranolol or adrenalectomy, nicotine was found to cause a
fall in GFR and decrease sodium and chloride excretion. It was
concluded that the stimulatory effect of nicotine on GFR, saliure-
sis and diuresis, was mediated by release of catecholamines from
the adrenal medulla, which exerted their effect via -adrenergic
receptors.
Concerning intrarenal hemodynamics in insulin-treated diabet-
ics, Ekberg et al [87] reported a significantly higher prevalence of
glomerular hyperfiltration (41% vs. 18%) in the smokers than in
the non-smokers. Furthermore, the GFR was directly dependent
on the amount of smoking. The fact that this correlation was not
found in users of snuff was interpreted to implicate that a
substance in tobacco smoke other than nicotine (which is ab-
sorbed by the nasal mucosa when snuffing) is responsible for these
effects. The increment of GFR induced by smoking may play a
role in the genesis of hyperfiltration as a potential mediator of
accelerated progression of chronic renal disease [88, 89].
A large body of information is available concerning the effects
of smoking on water diuresis. As early as 1945 Burn, Truelove and
Burn [901 reported that nicotine exerts an antidiuretic action in
rats and in humans. In rats of approximately 190 g body wt the
subcutaneous injection of a rather high dose of nicotine (0.25 mg)
induced an initial diuresis during the 15 minutes post-injection.
This was followed by an inhibition of the diuresis for about 45
minutes as compared to control rats. The authors interpreted the
short increment in diuresis as a result of the nicotine-induced
initial rise in blood pressure. When the pituitary gland was
removed, no inhibition of the diuresis occurred. These results
were confirmed in dogs by Cadnapaphornchai et a! [91], who
found evidence that nicotine increases vasopressin release by
altering cervical parasympathetic tone. Similar to their observa-
tions in the rat, Burn et al [90] reported that in men a diuresis
began when smoking started. Inhibition of diuresis then occurred
after 15 minutes of smoking, and the effect of three cigarettes
induced nearly complete inhibition during 2.5 hours, after which
the diuresis began again to reach a peak (4.5 hr). In some subjects
an antidiuretic effect was noted after smoking only one cigarette.
The antidiuretic effect of smoking was quite variable between
individuals. Antidiuresis is probably due to increased vasopressin
secretion during smoking [90, 92, 93]. In this context it is of
interest that antidiuresis has been proposed as a potential factor
in progression of chronic renal failure [94—96]. As to the mecha-
nism involved, it has been proposed that vasopressin increases
GFR inappropriately via modulating the activity of the tubuloglo-
merular feedback. This was thought to result from changes in urea
recycling [95].
Smoking is also associated with changes in proximal tubular
function, and there is indirect evidence of proximal tubular
damage in diabetic as well as in non-diabetic subjects [97—99].
These alterations of proximal tubular function include increased
excretion of N-acetyl-f3-glucosaminidase (NAG) [97, 98] and
impairment of organic cation transport [99]. The excretion rate of
NAG correlates significantly with the amount of tobacco con-
sumed [97]. It has to be pointed out, however, that the presence
of such low grade renal injury in smokers is even found in subjects
without primary renal disease [97].
Potential indirect mechanisms of smoking-induced renal injury
Effects of smoking on systemic hemodynamics
In view of the paramount importance of blood pressure on the
evolution of renal disease, the effects of smoking on blood
pressure are of considerable interest to the nephrologist.
Smokers have been reported not to be more frequently hyper-
tensive than non-smokers [100]; however, since the first decade of
this century, during smoking a transient increase of blood pressure
and heart rate has been known to occur [101]. These hemody-
namic actions are mediated via sympathetic activation [102] and
vasopressin release [90, 92, 93]. In addition, in patients with
primary hypertension an increase in cortisol, adrenocorticotrophic
hormone (ACTH) and plasma aldosterone concentration has
been noted during smoking [103]. Ambulatory blood pressure
measurements documented that the stimulation of the sympa-
thetic system causes persistent low grade elevation of blood
pressure during the daytime [104, 105], even though the hemody-
namic effects of one cigarette only last approximately 30 minutes.
The increase in systolic blood pressure and heart rate seems do be
related to nicotine, since no such changes occur when nicotine-
free cigarettes are smoked [106—108].
Furthermore, Hansen et al [109] reported that the normal
decrease in nighttime systolic and diastolic blood pressure was less
in healthy smokers than in non-smokers. However, in that study a
similar effect was not found in patients with IDDM who smoked
[109]. In contrast, however, in a preliminary communication by
Barna et al [110] the nighttime fall in blood pressure was less in
both smoking healthy volunteers as well as in smoking subjects
with IDDM. Full publication of the latter, well executed study is
awaited so that this interesting finding can be adequately evalu-
ated. Nevertheless, these results indicate that alterations in diur-
nal blood pressure rhythm are induced by smoking. Since the
deleterious role of elevated blood pressure on progression of
renal disease is well known [89, 111, 112], the intermittent and
persistent increase in blood pressure induced by smoking may well
contribute to progression of diabetic and non-diabetic renal
disease. This effect is particularly pertinent, since even minor
increments in blood pressure may affect the rate of progression
[113—115].
Adverse effects of smoking on diabetic nephropathy
The mechanisms by which smoking exerts its adverse effects on
renal function in diabetes mellitus have not been clarified. Mech-
anisms related to actions both on insulin sensitivity and effects on
systemic blood pressure and renal hemodynamics may be in-
volved.
Facchini et al [1161 studied the effect of smoking on insulin
sensitivity in 20 healthy smokers as compared to a matched group
of non-smokers; smokers had decreased insulin sensitivity and a
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higher prevalence of dyslipidemia. This observation was con-
firmed by Eliasson et a! [117], who reported that the smoking
habits in 57 middle-aged male smokers correlated with the degree
of insulin resistance and the levels of total cholesterol, low-density
lipoprotein cholesterol or triglycerides. Of interest, smoking and
percent body fat were the only independent factors related to the
degree of insulin resistance in this study. Finally, Dales et al [38]
reported higher serum and urine glucose in smokers one hour
after a 75 g glucose challenge. Since the degree of glycemic
control is decisive for the development of IDDM associated
nephropathy [1181, the effect of smoking could involve an effect on
insulin action. A relationship of smoking to insulin resistance,
however, has not been consistently confirmed [119—121], but the
weight of evidence seems to be in favor of an adverse effect.
Effects of smoking on platelets, thromboxane metabolism and the
endot helium
Smoking may indirectly damage the microvasculature (includ-
ing the glomerulus) in the kidney through its known effects on
platelet function, thromboxane metabolism and endothelial cell
function.
According to Hawkins smoking induces a thrombogenic state in
healthy male subjects [122]. Platelets of smokers were more
"active" as indicated by tests on clumping and maximum tensile
strength of the clot. The rate of initial clot formation was
increased, as was clot retraction. The most marked differences
between the smokers and non-smokers were observed 15 minutes
after smoking a cigarette. Enhanced platelet activity was particu-
larly prominent in the oldest and most heavy smoking subjects
with the longest smoking history. The finding of hyperactive
platelets in smokers was confirmed by others even in patients with
ESRD [123, 124].
Inhalation of nicotine-containing tobacco smoke, but not of
nicotine-free tobacco smoke, has been shown to reduce urinary
6-keto-PFG1,, a metabolite of prostacyclin PGI2 [125]. This
observation suggests that nicotine containing tobacco smoke
reduces vascular PGI7 production, a potential factor in the
development of atherosclerosis [125] and possibly also of glomer-
ular disease. Chronic smoking also has been reported to increase
the production of thromboxane A2, a potent vasoconstrictor [126,
127]. The deleterious synergism between activation of platelets
and diversion of arachidonic acid metabolites to proaggregatory
vasoconstrictors may be of particular importance in lupus nephri-
tis [77] and other inflammatory renal diseases.
In rats exposed to cigarette smoke, Pittilo et al [128] found
considerable changes of endothelial cell ultrastructure. These
changes were not observed when nicotine was injected subcuta-
neously to the rats, indicating that components of cigarette smoke
other than nicotine likely are responsible for these changes [1281.
On the other hand, Lin et al [129] administered nicotine to rats via
drinking water and noted increased frequency of endothelial cell
death resulting in enhanced transendothelial leakage of macro-
molecules. Transendothelial leakage of macromolecules, particu-
larly of low density lipoproteins, is important in the genesis of
atherosclerosis. In vitro studies with human endothelial cell cul-
tures indicate that plasma of smokers or human plasma exposed
to cigarette smoke are toxic to endothelial cells [130]. Extrusion of
glutathione from endothelial cells and activation of the hexose
monophosphate shunt, which is necessary to maintain glutathione
in the reduced state, point to the presence of oxidative stress that
may be imposed by the free radicals present in tobacco smoke
[130]. Furthermore, cigarette smoke induces the adhesion of
human monocytes to cultured human endothelial cells [131, 132].
This effect is possibly due to activation of protein kinase C,
leading to increased surface expression of the adhesive ligand
CDI lb on monocytes and its receptors ICAM-l and ELAM-1 on
endothelial cells [132]. There is also evidence that nicotine
increases the mitotic activity of endothelial cells, at least in a
rabbit model of fibromuscular plaque formation in the common
carotid artery [133]. In humans endothelial injury induced by
smoking is related to the quantity of cigarettes consumed, accord-
ing to studies that documented increased levels of von Willebrand
factor antigen in smokers [134, 135]. The number of desquamated
endothelial cells in the circulation increases significantly after
smoking only one cigarette [123]. No difference of the effect of
cigarette smoking on the endothelial cells was noted when healthy
subjects were compared with ESRD patients [124]. Smoking-
induced endothelial cell injury and interaction of white blood cells
with endothelial cells therefore could be involved in immune and
non-immune damage to the kidney.
Furthermore, cigarette smoking [136, 1371 and passive smoking
[138] impair endothelial cell-dependent vascular dilation in
healthy children and adults. This effect is dose-dependent. Endo-
thelial cell dependent and independent relaxation induced by
endogenous vasodilators are impaired in smokers as compared to
non-smokers [139]. Such impaired endothelial control of the
vascular tone has been confirmed by others [140]. Endothelial cell
dysfunction is an early feature of atherosclerosis and is also
implicated in the genesis of glomerular injury. Disturbed active
vasodilation is also deleterious for coronary arteries [141, 1421 and
might be important in the genesis of altered renal hemodynamics
of smokers [87, 143].
This list of potential adverse effects of smoking is certainly not
complete. For instance some [144—146], but not all [147], authors
have found an altered immune response in smokers. This could be
relevant for immune-mediated renal diseases.
An overview of the known direct and indirect effects of smoking
on the kidney is given in Table 1.
Practical consequences
In view of the above evidence, which is impressive though
admittedly incomplete, nephrologists must not remain passive.
The costs resulting from smoking are enormous. This includes
medical costs and social costs due to mortality and morbidity. The
United States Office of Technology Assessment calculated that
smoking costs the United States anywhere between $39 billion
and $96 billion annually [148], even when the renal complications
are not taken into consideration. The amount of human suffering
resulting from the sequelae of smoking is enormous but cannot be
quantitated.
In regards to the proportion of health costs from renal failure
that are due to smoking, we offer the following cautious and
conservative estimate. In the Federal Republic of Germany 40,000
patients are currently on dialysis, approximately 40% of whom
(according to a survey of ours) have a history of smoking, that is,
16,000. Approximately 25% continue to smoke on renal replace-
ment therapy (RRT). If the relative risk of renal failure in
smokers is increased by a factor of 1.5 [39], uremia could have
been postponed or even avoided by cessation of smoking [59] in
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Table 1. Direct and indirect effects of smoking (and nicotine) on the
kidney
Effects of smoking (and nicotine)
on the kidney Reference
Increase in GFR [86, 87]
Increase in urine flow [861
Increase in Na and C1 excretion [861
Antidiuretic action [90, 91]
Increased vasopressin secretion [90-93]
Increased plasma cortisol concentration [103]
Increased plasma ACTH concentration [103]
Increased plasma aldosterone [1031
concentration
Alterations in proximal tubular function [97—991
Activation of the sympathetic nerve [102]
system
Transient increase in systemic blood [101, 108]
pressure and heart rate
Persistent low-grade elevation of blood [104, 1051
pressure during daytime
Lowering of night/day ratio of systolic and [109, 1101
diastolic blood pressure
Decreased insulin sensitivity [116, 1171
Increased prevalence of dyslipidemia [1161
Increased platelet activity [122—124]
Reduction of vascular PGI2 production [125]
Increased production of thromboxane A2 [126, 127]
Direct toxic effects on endothelial cells [123, 124, 130, 134, 135]
Changes in endothelial cell ultrastructure [128, 1291
Induction of monocyte adhesion on [131, 132]
endothelial cells
Increased mitotic activity in endothelial [133]
cells
Impairment of endothelial cell-dependent [136—138, 140]
vascular dilation
Alterations of the immune response [144—146]
Abbreviations are: GFR, glomerular filtration rate; ACTH, adrenocor-
ticotrophic hormone; PGI2, prostaglandin 12.
approximately 5,000 patients. With an annual dialysis cost of
Deutsche Mark (DM) 80,000, the annual costs from this compli-
cation alone would amount to DM 400 million ($261 million). If
one restricts analysis to patients who continue to smoke on RRT
the number would still be DM 250 million ($163 million). In the
USA there are currently 195,000 dialysis patients, of which 18%
smoke (35,000 patients). With a risk factor of 1.5, uremia could
potentially have been postponed or even avoided by cessation of
smoking in approximately 11,667 patients. With an annual dialysis
cost per patient of $47,000 the annual cost of this complication
alone would be $548,349,000. This calculation does not consider
patients who have a history of smoking, but stopped smoking
before starting with RRT.
Against this background it is of some interest to examine how
well medical advice to stop smoking is heeded. In the USA
approximately 27% of patients with diabetes mellitus report
smoking cigarettes [40]. In Uppsala, Sweden, the prevalence of
heavy smoking (> 15 cigarettes/day) among 260 diabetic patients
was 11% in females and 20% in males [149]. These numbers must
be interpreted against the background that diabetologists appre-
ciate that smoking increases the risk of (i) early death, as well as
(ii) the risk of diabetic nephropathy and of other diabetic com-
plications. As discussed above, there is evidence that cessation of
smoking is beneficial for renal function in diabetic patients. It is
plausible to assume that this may also be true for non-diabetic
patients. Apart from its renal effects, cessation of smoking also
reduces the risk of premature death due to cardiovascular com-
plications. In dialyzed IDDM patients smoking has been shown to
increase the relative risk of myocardial infarction by a factor of 2.6
[150]. This has also been confirmed in hemodialyzed patients with
NIDDM [151].
Why do patients continue to smoke despite medical advice to
do the contrary? The major problem is that nicotine is addictive.
Recently some tantalizing new information has been published
concerning potential neuronal and molecular mechanisms of
smoking addiction. Specifically, inhibition of monoamine oxidase
B in the brains of smokers was found [281, suggesting that the
increase in brain dopamine may be due both to increased secre-
tion and decreased degradation. The addictive potential of smok-
ing is dramatically illustrated by the observation that in Germany
20% of cardiac transplant recipients resume smoking after cardiac
transplantation (R. Korfer, Bad Oeynhausen, Germany; personal
communication). In addition, smokers who quit have a higher
odds ratio (2.4 for men and 2.0 for women) to become overweight,
as has been shown in a study of Flegal et al [152]. This problem
might also be responsible to some extent for failed attempts to
stop smoking.
Apart from the unquestionable addictive potential, there is also
a deficit in health education about the deleterious effect of
smoking for diabetic and renal patients. As recently reported by
Malarcher et al [1531, patients with diabetes in the USA are still
as likely to smoke as those without diabetes, and this is the
experience in Germany as well [154]. More than 40% of smokers
with diabetes in the USA report never having received advice
from a physician to quit smoking [153]. It is hoped that this article
will alert nephrologists and diminish this proportion in renal
patients.
It is a sad fact that people do not learn from experience. As
early as 1907, Hesse [101] documented the stimulatory effect of
smoking on heart rate and blood pressure and advised against
smoking in patients with contracted kidneys. Furthermore, in
1945, based on their observations concerning the action of
nicotine on the kidney, Burn et al stated: "Our experiments do,
however, raise the question whether those with impaired kidney
function should be allowed to smoke" [90]. The answer to this
question should now be clear.
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